Enzyme - Switch sensors for therapeutic drug monitoring of immunotherapies

Amplification-Free Ratiometric Electrochemical Aptasensor for Point-of-Care Detection of Therapeutic Monoclonal Antibodies

“…To date, a variety of methods have been proposed for the detection of therapeutic mAbs. 8−10 Relative to the fluorescent, 11,12 colorimetric, 13,14 quartz crystal microbalance (QCM)-based, 15 liquid chromatography/mass spectrometry (LC/MS), 16,17 bioluminescent, 18,19 and chemiluminescent methods, 20 attention in the detection of therapeutic mAbs, 21−24 by virtue of their simple instrument, good portability, and high detection sensitivity and anti-interference capability. 25,26 For example, an electrochemical biosensor has been described by Ikebukuro et al for the detection of bevacizumab (BevMab).…”

“…To date, a variety of methods have been proposed for the detection of therapeutic mAbs. − Relative to the fluorescent, , colorimetric, , quartz crystal microbalance (QCM)-based, liquid chromatography/mass spectrometry (LC/MS), , bioluminescent, , and chemiluminescent methods, electrochemical biosensors have drawn more attention in the detection of therapeutic mAbs, − by virtue of their simple instrument, good portability, and high detection sensitivity and anti-interference capability. , For example, an electrochemical biosensor has been described by Ikebukuro et al for the detection of bevacizumab (BevMab) . In this method, DNA aptamers that can specifically bind to the complementarity-determining region (CDR) of BevMab were conjugated to magnetic beads via the biotin–streptavidin interactions and were used for the capture of BevMab, to which the alkaline phosphatase (ALP)-conjugated secondary antibodies were then attached; in the presence of p -aminophenyl phosphate (pAPP) as the substrate of ALP, the resulting products p -aminophenol (pAP) were then electrochemically oxidized for the quantitative detection of BevMab.…”